SCHEMBL4304502

SCHEMBL4304502

OCCc1cc(C#Cc2ccccc2)ccc1OC(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.41
FFAR4 Q5NUL3 3/20 0.41
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
ACACB O00763 1/20 0.38
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HNF4A P41235 1/20 0.34
HAO1 Q9UJM8 1/20 0.34
ASIC3 Q9UHC3 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306233 0.87 FFAR1 (0.39) FFAR1FFAR4PDE4APDE4BPDE4C
SCHEMBL4309349 0.84 ACACB (0.37) FFAR1FFAR4PDE4APDE4BPDE4C
SCHEMBL22994433 0.77 NTRK1 (0.38) PDE4APDE4BPDE4CPDE4DHTT
SCHEMBL29474958 0.75 SLC6A2 (0.41) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL3361287 0.75 SLC6A2 (0.41) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4312471 0.75 BACE1 (0.40) FFAR1ACACBMAPTHNF4AHAO1
SCHEMBL4308568 0.74 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL20303591 0.73 KMT2A (0.47) PDE4APDE4BPDE4CPDE4DPPARG
SCHEMBL3357880 0.73 USP28 (0.40) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4304391 0.72 ACACB (0.40) FFAR1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP FFAR1 3148/4885FFAR4 3488/4885PDE4A 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.